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Introduction 
Allergy and autoimmunity are rapidly 
increasing in all societies world-wide (1, 2). 
The identification of clinically relevant 
specific antibodies in patient serum is crucial 
for current diagnostics of allergy and 
autoimmunity. ImmunoCap 250 by Thermo 
Fisher is a singleplex assay system currently 
used in clinical labs, which  deliver around 
400-2000 results per week (3, 4). In this 
study we have investigated antigen 
component diagnostics for patients with 
allergy to egg and peanut and patients with 
autoimmune coeliac disease, which is 
characterised by sensitivity to gluten from 
dietary wheat, barley and rye. Uncontrolled 
coeliac disease can lead to developmental 
retardation in children and malnutrition in 
adults. Unmanaged allergy may lead to fatal 
anaphylaxis. To address these global health 
problems biomedical teams are constantly 
exploring ways to develop current tests. In 
collaboration with biomedical scientists from 
NGH, our students investidated if allergen 
component diagnostics could add value to 
current ImmunoCap tests.
Results 
This study compared the response values 
given from EliA IgA Celikey and EliA IgA 
GliadinDP ImmunoCAP 250 assays in 37 
serum samples, including both adult (>16 
years) and paediatric populations (<16 
years). The results showed that 
sensitivity was slightly higher in EliA IgA 
Celikey (Figure 2), and that there was a 
positive correlation in the response 
values between the two tests. 
The results of the EliA GliadinDP assay 
showed that there is greater sensitivity 
with the adult coeliac disease positive 
cohort as compared to the child coeliac 
disease positive cohort. EliA IgA GliadinDP 
assay gave diagnostic sensitivity of 
88.23% and all samples were correctly 
identified as positive with the EliA IgA 
Celikey assay (diagnostic sensitivity of 
100%).  
In peanut allergy testing 36% samples had 
a strong positive reaction with Ara h 1, 2 
or both, 7% samples had a positive 
reaction for all allergen components.  
In egg white allergy testing 62.5% 
samples had a positive reaction with all 
three allergens, 12.5% samples had a 
positive reaction to Gal d 1 and Gal d 2, 
12.5% samples had a positive reaction to 
Gal d 2 and Gal d 3, 12.5% had a positive 
reaction to Gal d 2 alone. Interestingly, 
all 100% of patients produced a positive 
reaction with allergen component Gal d 
2.
Aims 
This study was aimed to explore ImmunoCap 
component diagnostics in allergy and 
autoimmunity by exploring if EliA IgA Gliadin 
could complement significantly to current 
diagnostic tests for coeliac disease as well as 
to determine if egg and peanut allergen 
component detection could be more 
advanced that whole allergen testing. 
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Discussion 
 One of the hallmark characteristics 
of allergy and autoimmunity is the 
presence of specific antibodies of 
high affinity in patient serum, which 
can be used in the diagnostics. 
  The first-line serological test for 
coeliac disease is an anti-tTG ELISA 
cap (EliA IgA Celikey). Positive tTG 
tests are confirmed with a positive 
EMA (endomysial antibodies) result 
and a diagnosis of coeliac disease is 
only made after intestinal biopsy 
has shown the presence of villous 
atrophy. Deamidated gliadin assay 
(EliA IgA GliadinDP) has been 
suggested to be a more reliable 
method of detecting the disease, 
with increased specificity and a high 
sensitivity. Our study indicates that 
it would possibly be of greater 
benefit to run the EliA IgG GliadinDP 
test alongside the EliA IgA Celikey 
assay, as this should increase 
sensitivity and potentially remove 
the need for total IgA testing. 
Endomysial antibodies are still 
required as a confirmatory test in 
those patients with positive EliA IgA 
Gliadin test. For allergy samples, we 
found that component diagnosis may 
complement current diagnostic tests 
rather than replace them.
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Figure 1. Specific antibodies (IgA for coeliac 
disease and IgE for allergy) can be detected 
using ImmunoCap 250.
Figure 2. Example of EliA IgA Celikey and EliA 
IgA Gliadin results in paediatric patients with 
coeliac disease, showing a greater sensitivity 
with the EliA IgA Celikey assay.
Methods 
Blood samples  (31 for allergy and 37 for 
coeliac disease) were collected into gel 
vacutainers, which were then centrifuged at 
3000rpm for 10 minutes  
to separate serum. These samples were 
then stored at -20°C until needed for 
testing using the ImmunoCAP 250. The 
samples were used in line with the 
hospital laboratory protocols, rules and 
ethical procedures of both DMU and NGH. 
Samples were incubated with peanut (Ara 
h 1, 2 and 8) and egg white (Gal d 1, 2 
and 3) allergens as well as human 
recombinant tissue transglutaminase (tT) 
and synthetic deaminated gl iadin 
peptides to identify specific antibody- 
mediated reactions (Figure 1).
